Found: 17
Select item for more details and to access through your institution.
Humanistic and economic burden of nausea and vomiting among migraine sufferers.
- Published in:
- Journal of Pain Research, 2017, v. 10, p. 689, doi. 10.2147/JPR.S124683
- By:
- Publication type:
- Article
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 4, p. 662, doi. 10.1111/head.14097
- By:
- Publication type:
- Article
Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2019, v. 59, n. 10, p. 1743, doi. 10.1111/head.13654
- By:
- Publication type:
- Article
Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.
- Published in:
- Headache: The Journal of Head & Face Pain, 2019, v. 59, n. 6, p. 880, doi. 10.1111/head.13534
- By:
- Publication type:
- Article
The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post‐Hoc Analyses on the First 3 Weeks of Treatment.
- Published in:
- Headache: The Journal of Head & Face Pain, 2019, v. 59, n. 3, p. 383, doi. 10.1111/head.13446
- By:
- Publication type:
- Article
Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.
- Published in:
- Headache: The Journal of Head & Face Pain, 2017, v. 57, n. 9, p. 1375, doi. 10.1111/head.13156
- By:
- Publication type:
- Article
A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients.
- Published in:
- Headache: The Journal of Head & Face Pain, 2016, v. 56, n. 8, p. 1300, doi. 10.1111/head.12895
- By:
- Publication type:
- Article
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial.
- Published in:
- JAMA Neurology, 2023, v. 80, n. 11, p. 1145, doi. 10.1001/jamaneurol.2023.3542
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 82, n. 1, p. 108, doi. 10.1111/bcp.12941
- By:
- Publication type:
- Article
Capturing seizures in clinical trials of antiseizure medications for KCNQ2‐DEE.
- Published in:
- Epilepsia Open, 2021, v. 6, n. 1, p. 38, doi. 10.1002/epi4.12466
- By:
- Publication type:
- Article
From LBR-101 to Fremanezumab for Migraine.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
- Published in:
- Cephalalgia, 2020, v. 40, n. 5, p. 470, doi. 10.1177/0333102419885905
- By:
- Publication type:
- Article
Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects.
- Published in:
- 2018
- By:
- Publication type:
- journal article
First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica.
- Published in:
- PLoS ONE, 2015, v. 10, n. 5, p. 1, doi. 10.1371/journal.pone.0125034
- By:
- Publication type:
- Article